Introduction
Elopag 20 mg is identified as a medicine containing eltrombopag, an oral thrombopoietin receptor agonist. It is used in selected patients with certain conditions involving low platelet counts or impaired blood-cell production, depending on the applicable product authorization.
Eltrombopag works by activating the thrombopoietin receptor and supporting the production of platelets in the bone marrow. Although this action may help reduce bleeding risk in appropriate patients, the medicine can also cause unwanted effects.
Side effects vary from person to person. Some patients may experience mild symptoms, while others may develop reactions requiring medical assessment. Important potential risks include liver problems, excessive increases in platelet counts and blood clots.
Understanding possible adverse reactions helps patients recognize warning signs and know when to contact a healthcare professional. Regular monitoring is an essential part of treatment.
Important: This page provides general information about possible eltrombopag side effects. The complete safety profile of the specific Elopag 20 mg product has not been independently verified here. Always consult the product leaflet supplied with the medicine and follow the advice of the prescribing healthcare professional.
1. Common Side Effects of Elopag
Some patients taking eltrombopag experience mild or moderate side effects. These reactions may improve as treatment continues, but persistent or worsening symptoms should be discussed with a healthcare professional.
Possible commonly reported reactions include:
Headache
Headache is a possible side effect of eltrombopag. It may be mild or occasionally more troublesome.
Patients should inform their healthcare professional if headaches are persistent, severe, unusual or associated with other symptoms.
Nausea
Some patients may experience nausea or an unsettled stomach during treatment.
If nausea continues, affects eating or drinking, or becomes severe, medical advice may be needed.
Diarrhoea
Diarrhoea may occur during treatment. Persistent diarrhoea can cause dehydration, particularly in patients who are already unwell.
Patients should seek medical advice if diarrhoea is severe, prolonged or accompanied by dizziness, weakness or signs of dehydration.
Fatigue
Fatigue or unusual tiredness may occur. It can also be related to the underlying condition being treated.
Report significant or worsening tiredness, especially when it occurs with jaundice, abdominal pain or other new symptoms.
Cough and respiratory symptoms
Some patients may experience cough or upper respiratory tract symptoms. These can have several possible causes.
Contact a healthcare professional if symptoms are persistent, severe or accompanied by fever or breathing difficulties.
Muscle pain
Muscle aches or discomfort may occur. Patients should report persistent or severe muscle symptoms, particularly if they develop suddenly or interfere with daily activities.
Back pain
Back pain has been reported in patients receiving eltrombopag. It may be mild or may require assessment if persistent or severe.
Abdominal discomfort
Some patients experience stomach discomfort or abdominal pain. Severe, persistent or unexplained abdominal pain should not be ignored.
2. Serious Side Effects of Elopag
Although not every patient experiences serious reactions, eltrombopag has important safety risks that require medical supervision.
Liver problems and liver injury
Eltrombopag can cause abnormalities in liver function tests and, in some cases, serious liver injury.
Possible warning signs include:
- Yellowing of the skin or eyes.
- Dark-coloured urine.
- Unusual or persistent tiredness.
- Pain in the upper right area of the abdomen.
- Loss of appetite.
- Persistent nausea.
- Unexplained changes in general health.
Patients should report these symptoms promptly. Liver function tests may be required before and during treatment.
Blood clots
Eltrombopag can increase the risk of blood clots in some patients. These complications are known as thrombotic or thromboembolic events.
A blood clot may develop in different parts of the body and can become life-threatening.
Possible warning signs include:
- Sudden chest pain.
- Shortness of breath.
- Painful swelling in one leg.
- Sudden weakness or numbness.
- Sudden difficulty speaking.
- Sudden vision changes.
- Severe or unexplained abdominal pain.
Seek urgent medical attention if these symptoms occur.
Excessively high platelet counts
Eltrombopag stimulates platelet production. If platelet counts become too high, the risk of blood clots may increase.
Doctors monitor platelet counts and adjust treatment when necessary. Patients should never increase their dose independently.
Worsening low platelet counts after stopping treatment
Platelet counts may fall after eltrombopag is discontinued. In some patients, this may increase the risk of bleeding.
Do not stop treatment without discussing it with the prescribing healthcare professional. Follow-up blood tests may be necessary after treatment ends.
Serious allergic reactions
A severe allergic reaction may cause:
- Swelling of the face, lips, tongue or throat.
- Difficulty breathing.
- Severe rash.
- Sudden dizziness or fainting.
These symptoms require emergency medical attention.
3. Side Effects That Require Immediate Medical Attention
Some symptoms should be treated as urgent warning signs rather than ordinary medicine-related discomfort.
Seek emergency medical assistance if you experience:
- Chest pain or sudden difficulty breathing.
- Sudden weakness, numbness or difficulty speaking.
- Severe swelling or pain in one leg.
- Yellowing of the skin or eyes with other signs of liver injury.
- Severe abdominal pain.
- Heavy or uncontrolled bleeding.
- Swelling of the face or throat or difficulty breathing after taking the medicine.
Do not wait for a scheduled appointment if a serious reaction is suspected.
4. Liver-Related Side Effects
Liver safety is an important consideration when using eltrombopag.
The medicine can cause increases in liver enzymes and other abnormalities in liver function tests. In some cases, more serious liver injury may occur.
Before treatment, healthcare professionals may assess liver function. Additional blood tests may be performed during treatment to identify changes early.
Patients should tell their doctor if they have:
- Existing liver disease.
- A history of hepatitis.
- Previous abnormal liver function tests.
- Regular alcohol consumption.
- Other medicines that may affect the liver.
Do not assume that symptoms such as fatigue or nausea are harmless if they occur with dark urine, jaundice or abdominal pain.
5. Blood Clotting Risks
Eltrombopag increases platelet production, but a higher platelet count is not always better.
Excessive platelet increases may contribute to blood clot formation. However, thrombotic events can also occur in patients whose platelet counts are not extremely high.
Patients with a history of blood clots, cardiovascular disease or other clotting risk factors should discuss their medical history before treatment.
Healthcare professionals may consider:
- Previous deep vein thrombosis.
- Previous pulmonary embolism.
- Stroke history.
- Cardiovascular conditions.
- Other clotting risk factors.
- Current platelet count and treatment response.
The prescribed dose should be adjusted according to clinical monitoring rather than increased to achieve a normal platelet count.
6. Side Effects in Patients with Different Medical Conditions
The experience of eltrombopag treatment may differ depending on the patient’s underlying disease and general health.
Patients with immune thrombocytopenia
Patients receiving eltrombopag for chronic immune thrombocytopenia may experience headache, nausea, diarrhoea, fatigue or other adverse reactions.
Their platelet counts should be monitored to guide treatment and help avoid excessive increases.
Patients with severe aplastic anemia
Patients with severe aplastic anemia may already have low levels of several types of blood cells.
Treatment requires specialist supervision, including assessment of blood counts and other relevant laboratory results. New or worsening symptoms should be reported promptly.
Patients with hepatitis C-associated thrombocytopenia
In applicable treatment settings involving chronic hepatitis C, liver-related monitoring is particularly important because the underlying disease and other treatments may also affect liver function.
The suitability of eltrombopag depends on the treatment context and applicable prescribing guidance.
7. Factors That May Affect Side Effects
Several factors can influence how a patient responds to eltrombopag.
Dose and treatment duration
The prescribed dose and duration may influence treatment response and the likelihood of certain adverse effects. Dosing should be individualized by a healthcare professional.
Liver function
Patients with liver impairment may require additional assessment and closer monitoring.
Other medicines
Some medicines may affect liver function, bleeding risk or other aspects of treatment. Patients should disclose all prescription medicines, over-the-counter products and supplements.
Mineral supplements and antacids
Calcium, iron, magnesium, aluminium and zinc can reduce eltrombopag absorption when taken too close to the medicine.
Patients should follow the exact spacing instructions provided with their prescribed product.
Existing medical conditions
A history of blood clots, cardiovascular disease, liver disease or other significant conditions may affect treatment decisions.
8. How to Manage Mild Side Effects
Patients should not try to manage serious symptoms at home. For mild symptoms, the following general measures may help while awaiting medical advice.
- Headache: Rest and discuss suitable pain relief with a healthcare professional.
- Nausea: Ask a healthcare professional whether dietary adjustments may help.
- Diarrhoea: Maintain appropriate fluid intake and seek advice if symptoms persist.
- Fatigue: Allow sufficient rest and report significant or unexplained tiredness.
- Muscle or back pain: Discuss persistent discomfort with a healthcare professional.
- Abdominal discomfort: Report symptoms that are severe, persistent or worsening.
Do not start additional medicines to treat side effects without checking for possible interactions.
9. Importance of Regular Monitoring
Regular monitoring helps healthcare professionals evaluate treatment response and identify possible adverse reactions.
Platelet count monitoring
Blood tests help determine whether platelet counts are increasing appropriately. The results may guide dose changes or temporary treatment interruption.
Liver function monitoring
Liver function tests help identify possible liver-related problems. Patients should complete the recommended tests even if they feel well.
Clinical assessment
During follow-up appointments, healthcare professionals may ask about:
- Bruising or bleeding.
- Symptoms of blood clots.
- Abdominal discomfort.
- Fatigue.
- New or worsening symptoms.
- Other medicines being taken.
- Changes in general health.
Patients should attend appointments and follow the recommended monitoring schedule.
10. When to Contact Your Doctor
Contact your healthcare professional if you experience:
- Persistent nausea or diarrhoea.
- Frequent headaches.
- Unusual fatigue.
- New or unexplained bruising.
- Nosebleeds or gum bleeding.
- Persistent abdominal discomfort.
- New swelling or pain in a limb.
- Any unusual symptom that develops after starting treatment.
For chest pain, breathing difficulty, sudden neurological symptoms, severe bleeding or signs of a serious allergic reaction, seek emergency medical assistance.
11. Can Elopag Side Effects Be Prevented?
Not all side effects can be prevented. However, careful prescribing and monitoring may help reduce certain treatment-related risks.
Patients can support safer treatment by:
- Taking only the prescribed dose.
- Following the product-specific administration instructions.
- Completing recommended blood tests.
- Reporting new symptoms promptly.
- Informing the doctor about all medicines and supplements.
- Avoiding unapproved dose changes.
- Following instructions about calcium and mineral-containing products.
- Keeping scheduled follow-up appointments.
Never take another person’s medicine or share your prescribed treatment.
12. Frequently Asked Questions About Elopag Side Effects
What are the common side effects of Elopag 20 mg?
Possible side effects associated with eltrombopag include headache, nausea, diarrhoea, fatigue, cough, muscle pain, back pain and abdominal discomfort. The specific side-effect profile may vary by indication and patient.
Can Elopag cause liver problems?
Yes. Eltrombopag can cause abnormal liver function tests and, in some cases, serious liver injury. Liver monitoring is an important part of treatment.
Can eltrombopag cause blood clots?
Yes. Blood clots are an important potential risk. Patients should seek urgent medical attention for symptoms such as chest pain, sudden breathing difficulty or painful swelling in one leg.
Does Elopag cause headaches?
Headache is a possible side effect of eltrombopag. Persistent, severe or unusual headaches should be discussed with a healthcare professional.
Can Elopag cause nausea and diarrhoea?
Nausea and diarrhoea are possible adverse reactions. Seek medical advice if these symptoms become severe, persistent or cause dehydration.
What should I do if I experience severe side effects?
Contact a healthcare professional immediately. For severe allergic reactions, chest pain, breathing difficulty, serious bleeding or possible blood clot symptoms, seek emergency medical assistance.
Can side effects continue after stopping eltrombopag?
Some effects may persist or require follow-up after treatment ends. Platelet counts can also fall after discontinuation. Follow the monitoring and follow-up instructions provided by your healthcare professional.
Should I stop taking Elopag if I experience a side effect?
Do not stop or change the dose without medical advice. If you experience a serious or potentially life-threatening reaction, seek urgent medical care.
Does everyone experience side effects from eltrombopag?
No. Some patients experience side effects, while others tolerate treatment without significant problems. Individual responses vary.
How are Elopag side effects monitored?
Healthcare professionals use platelet counts, liver function tests and clinical assessments to monitor treatment response and identify possible complications.
Medical Disclaimer
This page provides general educational information about possible side effects associated with eltrombopag. It does not replace the official prescribing information, product leaflet, medical diagnosis or professional advice.
The side effects described are associated with eltrombopag and should not be interpreted as a verified, complete adverse-reaction list for the specific Elopag 20 mg product. Product-specific safety information should be confirmed through its approved documentation.
Always consult a qualified healthcare professional before starting, changing or stopping treatment. Seek emergency medical attention for severe allergic reactions, symptoms of blood clots, serious bleeding or possible liver injury.
References
- U.S. Food and Drug Administration (FDA). PROMACTA (eltrombopag) Prescribing Information.
- DailyMed. Eltrombopag and PROMACTA drug labeling information.
- U.S. National Library of Medicine. Clinical drug information for eltrombopag.
- Published clinical guidance concerning immune thrombocytopenia and severe aplastic anemia.
- Relevant national regulatory information and approved eltrombopag product leaflets.
Editorial note: Confirm the adverse-reaction information against the current approved leaflet for the specific Elopag product and the regulations applicable in the country where it is marketed.